The purpose is to study the efficacy of end-ischemic dHOPE in reducing the incidence of NAS within six months after controlled DCD (Maastricht category III) liver transplantation. In this trial the donor livers will be perfused with an a-cellular solution (UW-MPS), at 10 – 12 degrees Celcius, just about two hours prior to the transplantation. The Liver Assist is the dedicated device for this trial.
The dHOPE trial is initiated by the University Medical Center Groningen (UMCG, The Netherlands). Other participating centers are: Erasmus MC (Rotterdam), UMC Leiden, the University Hospital of Leuven (Belgium) and the University Hospital of Ghent (Belgium).
More information about this trial can be found at the following websites:
ClinicalTrials.gov Identifier: NCT02584283